Published in Cancer Res on May 01, 1977
Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest (1980) 2.03
Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest (1981) 1.46
Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour. Br J Cancer (1979) 0.96
Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment. Cell Cycle (2016) 0.87
Effect of adriamycin on CFUGM at plasma concentrations found following therapeutic infusions. Br J Cancer (1984) 0.85
Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study. PLoS One (2015) 0.80
An evaluation of hepatic extraction and clearance of doxorubicin. Br J Cancer (1995) 0.77
Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol (1987) 0.76
Dosage adjustment in renal insufficiency. Br J Clin Pharmacol (1982) 0.76
A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model. Oncology (2012) 0.76
Cardiotoxic effects of anthracyclines. West J Med (1983) 0.75
Failure of liver function tests in predicting drug clearance of chemotherapeutic agents in a patient who had recovered from hepatic congestion. Br J Clin Pharmacol (2010) 0.75
Clinical correlates of in vitro drug sensitivities of ovarian cancer cells. Br J Cancer (1983) 0.75
Distribution of 4'epi-doxorubicin in human tissues. Br J Cancer (1983) 0.75
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res (1978) 2.24
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol (2012) 1.81
NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A (1979) 1.75
Bis-benzimidazole anticancer agents: targeting human tumour helicases. Anticancer Drug Des (1999) 1.66
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res (1974) 1.62
Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg (1990) 1.59
Biological and biochemical properties of Phaseolus vulgaris isolectins. J Biol Chem (1977) 1.55
Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem (1984) 1.54
Purification of the phytohemagglutinin family of proteins from red kidney beans (Phaseolus vulgaris) by affinity chromatography. Biochim Biophys Acta (1975) 1.52
Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg (1986) 1.50
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Adriamycin cardiomyopathy--risk factors. Cancer (1977) 1.46
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol (1999) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol (2010) 1.42
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Combination chemotherapy in adult desmoid tumors. Cancer (1993) 1.36
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol (1997) 1.34
Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer (1999) 1.31
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol (1999) 1.29
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol (1984) 1.28
Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery (1994) 1.28
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol (2009) 1.27
Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods. Cancer Chemother Rep (1970) 1.26
Doxorubicin-induced congestive heart failure in adults. Cancer (1985) 1.26
Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol (1999) 1.25
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (1993) 1.25
Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol (1977) 1.22
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. Cancer Treat Rep (1977) 1.21
Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA (1988) 1.20
Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther (1973) 1.19
Hepatic stimulator substance: physicochemical characteristics and specificity. Am J Physiol (1982) 1.18
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol (1994) 1.17
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol (2001) 1.17
Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes. Science (1976) 1.16
The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther (1971) 1.16
Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol (1995) 1.15
Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos (1976) 1.14
Myxoid liposarcoma. Experience with chemotherapy. Cancer (1994) 1.13
Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer (1993) 1.09
Arterial occlusion: management of giant cell tumor and aneurysmal bone cyst. AJR Am J Roentgenol (1981) 1.09
Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer (1996) 1.05
Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol (1997) 1.04
Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors. Cancer (1990) 1.03
Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer (2001) 1.02
Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.01
Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 1.01
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol (1995) 1.00
Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol (1982) 1.00
Rat liver daunorubicin reductase. An aldo-keto reductase. J Biol Chem (1974) 0.99
Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol (1994) 0.99
Daunomycin metabolism in rat tissue slices. J Pharmacol Exp Ther (1970) 0.99
Adriamycin and daunorubicin disposition in the rabbit. J Pharmacol Exp Ther (1974) 0.99
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol (1992) 0.99
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep (1979) 0.98
Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann Thorac Surg (1991) 0.98
Ectopic production of the beta-subunit of human chorionic gonadotropin in osteosarcoma. Arch Pathol Lab Med (1989) 0.98
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol (1995) 0.97
Sarcoma of the stomach: clinicopathologic study of 43 cases. J Surg Oncol (1980) 0.97
Primary extraskeletal osteosarcoma--experience with chemotherapy. J Natl Cancer Inst (1995) 0.97
A phase II trial of taxol in metastatic melanoma. Cancer (1990) 0.97
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol (2000) 0.96
Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos (1980) 0.96
The natural history of resectable metastatic melanoma (Stage IVA melanoma). Cancer (1982) 0.96
A 15-year experience with chemotherapy of patients with paraganglioma. Cancer (1995) 0.96
Nuclear catalyzed antibiotic free radical formation. Cancer Res (1982) 0.95
Rat liver aldehyde reductase. Biochem Pharmacol (1977) 0.95
Microsomal synthesis of fatty acid amides. J Biol Chem (1966) 0.95
Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer (1984) 0.95
Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res (1983) 0.95
Primary soft tissue sarcoma of the breast. Curr Treat Options Oncol (2001) 0.95
The natural history of metastatic synovial sarcoma: experience of the Southwest Oncology group. Clin Orthop Relat Res (1982) 0.94
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res (1984) 0.94
Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. Cancer (1980) 0.94
Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor. Ann Intern Med (1990) 0.93
Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol (1982) 0.92
Recovery of sperm production after chemotherapy for osteosarcoma. Cancer (1989) 0.92
Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res (1972) 0.91
Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol (1995) 0.91
A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol (1989) 0.91
Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep (1980) 0.90
Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Magn Reson Imaging Clin N Am (1995) 0.90
Cytology of malignant melanoma of soft parts: fine-needle aspirates and exfoliative specimens. Diagn Cytopathol (1993) 0.90
Daunorubicinol, a major metabolite of daunorubicin: isolation from human urine and enzymatic reactions. J Pharmacol Exp Ther (1971) 0.90
Recombinations of subunits of Phaseolus vulgaris isolectins. J Biol Chem (1977) 0.89
A soluble dihydrofolate reductase from human placenta: purification and properties. Arch Biochem Biophys (1971) 0.89
Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharmacol (1981) 0.89